Back to Search
Start Over
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
- Source :
- Mall, Marcus A; Brugha, Rossa; Gartner, Silvia; Legg, Julian; Moeller, Alexander; Mondejar-Lopez, Pedro; Prais, Dario; Pressler, Tacjana; Ratjen, Felix; Reix, Philippe; Robinson, Paul D; Selvadurai, Hiran; Stehling, Florian; Ahluwalia, Neil; Arteaga-Solis, Emilio; Bruinsma, Bote G; Jennings, Mark; Moskowitz, Samuel M; Noel, Sabrina; Tian, Simon; Weinstock, Tanya G; Wu, Pan; Wainwright, Claire E; Davies, Jane C (2022). Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. American Journal of Respiratory and Critical Care Medicine, 206(11):1361-1369.
- Publication Year :
- 2022
Details
- Database :
- OAIster
- Journal :
- Mall, Marcus A; Brugha, Rossa; Gartner, Silvia; Legg, Julian; Moeller, Alexander; Mondejar-Lopez, Pedro; Prais, Dario; Pressler, Tacjana; Ratjen, Felix; Reix, Philippe; Robinson, Paul D; Selvadurai, Hiran; Stehling, Florian; Ahluwalia, Neil; Arteaga-Solis, Emilio; Bruinsma, Bote G; Jennings, Mark; Moskowitz, Samuel M; Noel, Sabrina; Tian, Simon; Weinstock, Tanya G; Wu, Pan; Wainwright, Claire E; Davies, Jane C (2022). Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. American Journal of Respiratory and Critical Care Medicine, 206(11):1361-1369.
- Notes :
- application/pdf, info:doi/10.5167/uzh-229480, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1482455833
- Document Type :
- Electronic Resource